



Fatal intracranial aneurysm rupture after thrombolytic treatment for ischemic stroke: a case report and literature review

Vladimír Beneš 3rd¹ · Lubomír Jurák¹ · Jaroslav Jedlička¹ · Jan Dienelt² · Petr Suchomel¹

Received: 1 February 2019 / Accepted: 24 April 2019 / Published online: 7 May 2019
© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Abstract

Intravenous thrombolysis is a proven treatment of acute ischemic stroke. Its complications include intracranial hemorrhage; the risk may be increased in the presence of an unruptured aneurysm. We present a case report of a patient who suffered fatal subarachnoid hemorrhage after thrombolysis from a known aneurysm. A history of recent previously inexperienced headaches was revealed retrospectively, suggestive of sentinel bleedings. A similar patient was identified in the literature; we thus propose that this history should be excluded in patients harboring an aneurysm considered for thrombolytic treatment.

Keywords Aneurysm · Stroke · Subarachnoid hemorrhage · Thrombolysis · Outcome

Introduction

Administration of intravenous tissue plasminogen activator (tPA) is a proven treatment of acute ischemic stroke [7, 17]. However, its use is not without risks and can lead to potentially serious complications including intracranial hemorrhage. The rate of hemorrhage varies between 2 and 7% [22] depending on definition and patient population. Increased risk may be associated with advanced age, hypertension, anticoagulant use, large infarction volume, or underlying vascular pathology, such as unruptured intracranial aneurysm (UIA). Previously published guidelines list the presence of UIA as an exclusion criterion for intravenous tPA administration [3]. A revised statement considers this treatment reasonable even in the presence of UIAs smaller than 10 mm (class IIa, level of evidence C—limited data) [17].

Since stroke and UIAs share to some extent similar underlying risk factors, higher prevalence of UIAs among stroke victims is not surprising. Despite recent studies and guidelines suggesting that thrombolytic treatment in the presence of UIA is safe [2, 4, 5, 14, 17, 28], case reports of severe subarachnoid hemorrhage (SAH) following intravenous tPA administration are well recognized in the stroke literature [8, 18, 21].

The purposes of this study are to present a case report of fatal aneurysm rupture immediately following intravenous tPA treatment and to analyze similar patients from the literature with the aim of identifying specific factors that could precipitate aneurysm rupture.

Case report

A 70-year-old man presented with wake-up stroke with expressive aphasia and right-sided weakness. The initial computed tomography (CT) (Fig. 1a) showed no apparent ischemia or hemorrhage; CT angiography (CTA) (Fig. 1b) revealed a 3-mm large aneurysm of the C7 segment of the internal carotid artery and no major vessel occlusion. Intravenous administration of tPA (Actilyse®) was started; in total, 70 mg was planned and a bolus of 7 mg was administered after door-to-needle time of 35 min. Following administration of approximately half the planned amount, the patient suddenly lost consciousness with a Glasgow Coma Scale of 3. Emergent CT showed massive SAH (Fig. 1c). At this time, the patient exhibited clinical signs of brain death which was later

Vladimír Beneš 3rd and Lubomír Jurák contributed equally to this work and share first authorship

This article is part of the Topical Collection on *Vascular Neurosurgery - Aneurysm*

✉ Vladimír Beneš, 3rd
vladimir.benes@nemlib.cz

¹ Department of Neurosurgery, Regional Hospital Liberec, Husova 10, 460 01 Liberec, Czech Republic

² Department of Neurology, Regional Hospital Liberec, Husova 10, Liberec 460 01, Czech Republic




Fig. 1 **a** Initial CT showing no signs of subarachnoid hemorrhage on non-contrast CT scan at the level of the aneurysm. **b** Aneurysm of the internal carotid artery (arrow). **c** Massive subarachnoid hemorrhage after thrombolysis

confirmed by brainstem evoked potentials and formal angiography. Subsequent interview with the patient's family revealed a history of severe, previously unknown, headaches during the preceding week suggestive of repeated sentinel bleeding.

A literature review identified seven relevant articles describing additional eight patients similar to ours (Table 1) [8, 11, 13, 18, 21, 24, 27]. In addition, one patient experienced SAH after being treated with tPA for myocardial infarction [12]. Pretreatment CTA or formal angiography was performed in six patients (including ours), and in two cases, the aneurysm was distal to the occluded segment and could not be diagnosed on initial vessel imaging [13, 27]. The aneurysm was known in two patients at the start of thrombolytic treatment (present case and Shi et al. [24]), suspected in one [21], and initially missed and found in retrospect in another (a distal lenticulostriate artery aneurysm) [24]. Two aneurysms ruptured after direct intraarterial lysis of the occluded (and parent) artery [13, 21], and the remaining aneurysms ruptured after intravenous tPA administration. Following rupture of the aneurysm, six patients (as well as the patient treated for myocardial infarction) died as a direct consequence of SAH, one patient achieved good recovery without neurological deficit [27], and two patients were left severely disabled [11, 24]. The only common factor contributing to rupture we were able to identify among the reported patients is a history of recent, previously inexperienced, headaches in the presented case and the one reported by Rammos et al. [18].

Discussion

The prevalence of UIAs in the general population is approximately 2–3% [20, 26], but higher in the stroke population [2, 5, 14]; values of nearly 10% have been reported [4, 5, 14]; thus, the proportion of stroke patients harboring UIAs is by no means negligible. Furthermore, availability and widespread use of CTA in the diagnostic work-up of acute ischemic stroke will undoubtedly lead to increased detection of UIAs among stroke patients in the near future. As a consequence, stroke

physicians should be aware of possible risks associated with this condition and its influence on treatment complications and patient outcomes.

Several studies have shown that the presence of an UIA in patients undergoing tPA treatment does not negatively influence rates of intracranial hemorrhage, in-hospital mortality, and both discharge and 3-month mRS scores [1, 2, 4–6, 10, 14, 15, 23, 25, 28]. Thus, the presence of an UIA (smaller than 10 mm) is no longer considered a contraindication for tPA administration [17]. Given this growing body of literature concerning safety of tPA administration in the presence of an UIA, stroke physicians no longer hesitate to treat an acute condition (stroke) which can have profound negative impact on the patient's life rather than worry about an unspecified risk of rupture of (probably) chronic aneurysm. At the moment of presentation, stroke is the condition responsible for the immediate patient's status and as such, its treatment has absolute priority and is justified. Likewise, neurosurgeons do not hesitate to administer induced hypertension in the treatment of delayed ischemic neurological deficit after SAH even in the presence of another unruptured (and unsecured) aneurysm [9, 16, 19]. Similar to stroke, the risk of adverse outcome due to vasospasm-induced delayed ischemic neurological deficit is too high and the risk of rupture of an additional aneurysm at best rare.

Even though aneurysm rupture following thrombolysis is rare; its consequences are nearly always disastrous. We identified eight additional patients similar to the one reported in our case report; of these, only one achieved favorable recovery, six died and two were left severely disabled (88.9% rate of unfavorable outcome). We were unable to identify common factors that could contribute to rupture apart from history of recent sentinel headaches in our patient and the one reported by Rammos et al. [18]. In both of these cases, the history was established retrospectively and, due to aphasia, could not have been revealed during admission and before thrombolysis administration. On the other hand, the aneurysm that was diagnosed before tPA was started and had this history of recent thunderclap headaches been known, we would probably

Table 1 Summary of cases of aneurysm rupture after thrombolysis reported in the literature. (F female, M male, IU international units, NR not reported, tPA tissue plasminogen activator, IA intraarterial, IV intravenous, ME mechanical embolectomy, CE coil embolization, SAH subarachnoid hemorrhage, MCA middle cerebral artery, ACOM anterior communicating artery, PCOM posterior communicating artery, PICA posterior inferior cerebellar artery, ICA internal carotid artery, LSA lenticulostriate artery, mRS modified Rankin Scale)

| Author | Age, gender | Symptoms | Initial angiography | Treatment | Endovascular procedure | Aneurysm Size | Rupture timing | Outcome | Remark |
|-------------------------------|---------------|-----------------------------|---|----------------------------|------------------------|-----------------|----------------|----------------------|--|
| Matsumaru 1998 [13] | 52, F | Left hemiparesis | Right ICA occlusion, aneurysm not visible | 300,000 IU of urokinase IA | IA lysis | Right MCA | NR | Periprocedural Death | Multiple ruptures |
| Ritter 2003 [21] | 72, M | Right hemiparesis | Left MCA occlusion, aneurysm suspected | 2 × 5 mg tPA IV | IA lysis | Left MCA | 15 mm | Periprocedural Death | |
| Ramos 2012 [18] | 51, F | Right hemiparesis + aphasia | Not done | IV, dose NR | ME + CE after SAH | ACOM | 7 mm | Not specified | Recent sentinel headache retrospectively |
| Haji 2014 [8] | 71, M | Right hemiparesis + aphasia | Not done | 90 mg tPA IV | – | PCOM; PICA | 6 mm; 8.5 mm | 5 h | Death |
| Zaldivar-Jolissaint 2015 [27] | 71, F | Left hemiparesis | Right MCA occlusion, aneurysm not visible | 0.9 mg/kg tPA IV | Only angiography | Right MCA | 6 mm | 24 h | No deficit |
| Kim 2017 [11] | 51, M | Right hemiparesis + aphasia | Not done | 0.9 mg/kg tPA IV | – | Right MCA | 3 mm | 2 h | mRS 5 |
| Shi 2019 [24] | “Elderly”, NR | Left hemiplegia | No major vessel occlusion, aneurysm visible | IV tPA, dose NR | – | Right MCA /LSA | 5 mm | 2 h | Death |
| Present case | 70, M | Right hemiplegia | No major vessel occlusion, aneurysm missed | IV tPA, dose NR | – | Left distal LSA | 2 mm | 1.5 h | Bed-ridden |
| | | Right hemiparesis + aphasia | No major vessel occlusion, aneurysm visible | 35 mg tPA IV | – | Right ICA | 3 mm | 20 min | Death |
| | | | | | | | | | Aneurysm visible in retrospect |
| | | | | | | | | | Recent sentinel headache retrospectively |

consider direct endovascular procedure or conservative therapy. Excluding history of recent SAH headaches could be part of pretreatment work-up in stroke patients harboring an UIA before tPA is started. This information can be obtained from the patient or immediate family with relative ease, however should not cause significant delay in starting tPA administration. We are aware that such a generalization based on only two reported patients is a little daring, but the grievous outcome after aneurysm rupture likely justifies this simple measure.

Conclusions

Although the presence of an UIA smaller than 10 mm is not considered a contraindication for thrombolytic treatment in acute ischemic stroke, every effort should be made to exclude recent sentinel bleed when an UIA is diagnosed during initial diagnostic work-up. When the patient is unable to provide this information, the immediate family should be contacted if possible. These measures must not cause significant delay of thrombolytic therapy. If recent aneurysm rupture is suspected, other treatment options should be contemplated instead of intravenous thrombolysis.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval For this type of study, formal consent is not required.

Informed consent Informed consent was obtained from all individual participants included in the study.

References

- Chen F, Yan S, Jin X, Lin C, Cao J (2014) Post-thrombolysis hemorrhage risk of unruptured intracranial aneurysms. *Europ Neurol* 73:37–43
- Chiu WT, Hong CT, Chi NF, Hu CJ, Hu HH, Chan LA (2017) The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm. *PLoS One*
- Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE, American Heart Association Stroke C, Council on E, Prevention (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 47:581–641. <https://doi.org/10.1161/STR.000000000000086>
- Ding J, Han J, Jing Z, Jiang Y (2016) Is it dangerous to treat acute ischemic stroke by thrombolytic therapy in patients with comorbid intracranial aneurysms? *Am J Emerg Med* 34:636–642
- Edwards NJ, Kamel H, Josephson SA (2012) The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms A case series and review of the literature. *Stroke* 43:412–416. <https://doi.org/10.1161/STROKEAHA.111.634147>
- Goyal N, Tsivgoulis G, Zand R, Sharma VK, Barlinn K, Male S, Katsanos AH, Bodechtel U, Iftikhar S, Arthur A, Eljovich L, Alexandrov AW, Alexandrov AV (2015) Systemic thrombolysis in acute ischemic stroke patients with unruptured intracranial aneurysms. *Neurology* 85:1452–1458. <https://doi.org/10.1212/wnl.0000000000002068>
- Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 359:1317–1329
- Haji F, van Adel B, Avery M, Megyesi J, Young GB (2014) Intracranial aneurysm rupture following intravenous thrombolysis for stroke. *Can J Neurol Sci* 41:95–98
- Hoh BL, Carter BS, Ogilvy CS (2002) Risk of hemorrhage from unsecured, unruptured aneurysms during and after hypertensive hypervolemic therapy. *Neurosurgery* 50:1207–1211 discussion 1211–1202
- Kim JT, Park MS, Yoon W, Cho KH (2012) Detection and significance of incidental unruptured cerebral aneurysms in patients undergoing intravenous thrombolysis for acute ischemic stroke. *J Neuroimaging* 22:197–200. <https://doi.org/10.1111/j.1552-6569.2010.00560.x>
- Kim HJ, Kang D-W, Kwon SU, Kim JS, Jeon S-B (2017) Aneurysmal subarachnoid hemorrhage following intravenous thrombolysis in acute ischemic stroke. *J Neurocrit Care* 10:107–111. <https://doi.org/10.18700/jnc.170015>
- Lagares A, Gomez PA, Lobato RD, Alen JF, Campollo J, Benito-Leon J (1999) Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction. *Surg Neurol* 52:623–626
- Matsumaru Y, Hyodo A, Okazaki M, Nose T (1998) A pitfall of fibrinolysis. Aneurysms found after attempted fibrinolytic therapy of occluded arteries. *Interv Neuroradiol* 4:165–169. <https://doi.org/10.1177/159101999800400209>
- Mittal MK, Seet RC, Zhang Y, Brown RD Jr, Rabinstein AA (2013) Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms. *J Stroke Cerebrovasc Dis* 22:639–643. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.01.009>
- Mowla A, Singh K, Mehla S, Ahmed MK, Shirani P, Kamal H, Krishna C, Sawyer RN, Ching M, Siddiqui AH, Levy EI, Snyder KV, Crumlish A, Hopkins LN (2015) Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm? *Int J Stroke* 10:113–118. <https://doi.org/10.1111/ij.12616>
- Platz J, Guresir E, Vatter H, Berkefeld J, Seifert V, Raabe A, Beck J (2011) Unsecured intracranial aneurysms and induced hypertension in cerebral vasospasm: is induced hypertension safe? *Neurocrit Care* 14:168–175. <https://doi.org/10.1007/s12028-011-9510-2>
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL (2018) 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 49:e46–e99. <https://doi.org/10.1161/str.0000000000000158>
- Rammos SK, Neils DM, Fraser K, Klopfenstein JD (2012) Anterior communicating artery aneurysm rupture after intravenous thrombolysis for acute middle cerebral artery thromboembolism: case report. *Neurosurgery* 70:E1603–E1607

19. Reynolds MR, Buckley RT, Indrakanti SS, Turkmani AH, Oh G, Crobeddu E, Fargen KM, El Ahmadieh TY, Naidech AM, Amin-Hanjani S, Lanzino G, Hoh BL, Bendok BR, Zipfel GJ (2015) The safety of vasopressor-induced hypertension in subarachnoid hemorrhage patients with coexisting unruptured, unprotected intracranial aneurysms. *J Neurosurg* 123:862–871. <https://doi.org/10.3171/2014.12.JNS141201>
20. Rinkel GJ, Djibuti M, Algra A, van Gijn J (1998) Prevalence and risk of rupture of intracranial aneurysms: a systematic review. *Stroke* 29:251–256
21. Ritter MA, Kloska S, Konrad C, Droste DW, Heindel W, Ringelstein EB (2003) Rupture of a thrombosed intracranial aneurysm during arterial thrombolysis. *J Neurol* 250:1255–1256. <https://doi.org/10.1007/s00415-003-0177-2>
22. Seet RC, Rabinstein AA (2012) Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. *Cerebrovasc Dis* 34:106–114. <https://doi.org/10.1159/000339675>
23. Sheth KN, Shah N, Morovati T, Hermann LD, Cronin CA (2012) Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms. *Neurocrit Care* 17:199–203. <https://doi.org/10.1007/s12028-012-9734-9>
24. Shi H, Wee CK, John S (2019) Post-thrombolysis rupture of small lenticulostriate aneurysms: a report of 2 consecutive cases. *J Clin Neurosci* 60:148–150. <https://doi.org/10.1016/j.jocn.2018.10.087>
25. Shono Y, Sugimori H, Matsuo R, Fukushima Y, Wakisaka Y, Kuroda J, Ago T, Kamouchi M, Kitazono T, Fukuoka Stroke Registry I (2018) Safety of antithrombotic therapy for patients with acute ischemic stroke harboring unruptured intracranial aneurysm. *Int J Stroke*. <https://doi.org/10.1177/1747493018765263>
26. Vlak MH, Algra A, Brandenburg R, Rinkel GJ (2011) Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. *Lancet Neurol* 10:626–636
27. Zaldivar-Jolissaint JF, Messerer M, Bervini D, Mosimann PJ, Levivier M, Daniel RT (2015) Rupture of a concealed aneurysm after intravenous thrombolysis of a thrombus in the parent middle cerebral artery. *J Stroke Cerebrovasc Dis* 24:e63–e65. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.10.004>
28. Zhang CH, Li C, Wang YX, Chen Y, Dong Z, Zhang X, Zhang F, Yin H, Tong X, Wang J, Zhang PL (2015) Efficacy and safety of intravenous thrombolysis for the treatment of acute ischemic stroke patients with saccular intracranial aneurysms of ≤ 3 mm. *Cell Biochem Biophys* 72:889–893. <https://doi.org/10.1007/s12013-015-0557-0>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.